JP2006517591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517591A5 JP2006517591A5 JP2006503494A JP2006503494A JP2006517591A5 JP 2006517591 A5 JP2006517591 A5 JP 2006517591A5 JP 2006503494 A JP2006503494 A JP 2006503494A JP 2006503494 A JP2006503494 A JP 2006503494A JP 2006517591 A5 JP2006517591 A5 JP 2006517591A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- halo
- group
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- -1 alkyl luma Chemical compound 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 102000036530 EDG receptors Human genes 0.000 claims 2
- 108091007263 EDG receptors Proteins 0.000 claims 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000023320 Luma <angiosperm> Species 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 125000005730 thiophenylene group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44664803P | 2003-02-11 | 2003-02-11 | |
| US46480903P | 2003-04-21 | 2003-04-21 | |
| US47201203P | 2003-05-19 | 2003-05-19 | |
| PCT/US2004/004006 WO2004071442A2 (en) | 2003-02-11 | 2004-02-11 | Novel bicyclic compounds and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006517591A JP2006517591A (ja) | 2006-07-27 |
| JP2006517591A5 true JP2006517591A5 (https=) | 2010-04-22 |
| JP4505449B2 JP4505449B2 (ja) | 2010-07-21 |
Family
ID=32872761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503494A Expired - Fee Related JP4505449B2 (ja) | 2003-02-11 | 2004-02-11 | 新規二環式化合物および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7256206B2 (https=) |
| EP (1) | EP1594508B1 (https=) |
| JP (1) | JP4505449B2 (https=) |
| AU (1) | AU2004210697B2 (https=) |
| BR (1) | BRPI0407401A (https=) |
| CA (1) | CA2515638A1 (https=) |
| ES (1) | ES2393551T3 (https=) |
| MX (1) | MXPA05008531A (https=) |
| PL (1) | PL378134A1 (https=) |
| WO (1) | WO2004071442A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7456157B2 (en) * | 2003-02-18 | 2008-11-25 | Kyorin Pharmaceutical Co., Ltd. | Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| JP4740884B2 (ja) * | 2004-02-24 | 2011-08-03 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制性化合物および組成物 |
| CN101014329B (zh) | 2004-07-16 | 2010-09-08 | 杏林制药株式会社 | 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物 |
| EP1806338B1 (en) * | 2004-10-12 | 2016-01-20 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof |
| AU2005299851B2 (en) * | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| EP2592066B1 (en) * | 2004-12-13 | 2014-12-03 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medical use thereof |
| SI1932522T1 (sl) * | 2005-10-07 | 2012-08-31 | Kyorin Seiyaku Kk | Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| US20070191371A1 (en) * | 2006-02-14 | 2007-08-16 | Kalypsys, Inc. | Heterocyclic modulators of ppar |
| WO2007112322A2 (en) | 2006-03-28 | 2007-10-04 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
| MX2009001457A (es) | 2006-08-08 | 2009-02-19 | Kyorin Seiyaku Kk | Derivados de aminoalcohol e inmunosupresores que contienen lo mismo como ingrediente activo. |
| JP5188972B2 (ja) * | 2006-08-08 | 2013-04-24 | 杏林製薬株式会社 | アミノリン酸エステル誘導体及びそれらを有効成分とするｓ１ｐ受容体調節剤 |
| US8524917B2 (en) | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| CN101918360A (zh) | 2007-09-24 | 2010-12-15 | 阿勒根公司 | 具有1-磷酸-鞘氨醇(s1p)受体生物学活性的带芳基或者杂芳基基团的吲哚化合物 |
| EP2229361A1 (en) | 2008-01-03 | 2010-09-22 | Allergan, Inc. | Tetrahydroindoles having sphingosine-1-phosphate receptor activity |
| WO2009099174A1 (ja) | 2008-02-07 | 2009-08-13 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
| CN102089305A (zh) | 2008-05-08 | 2011-06-08 | 阿勒根公司 | 治疗用取代的1,7-联苯-1,2,3,5,6,7-六氢吡啶并[3,2,1-ij]喹啉化合物 |
| US8143291B2 (en) | 2008-05-09 | 2012-03-27 | Allergan, Inc. | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EA019252B1 (ru) | 2008-07-23 | 2014-02-28 | Арена Фармасьютикалз, Инк. | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ |
| SI2342205T1 (sl) | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| SG10201906876PA (en) | 2010-01-27 | 2019-09-27 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| SG183416A1 (en) | 2010-03-03 | 2012-09-27 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| WO2011133734A1 (en) | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| EP2619190B1 (en) | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| WO2018151834A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| CN112955431A (zh) | 2018-09-06 | 2021-06-11 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1229385C (zh) * | 1994-03-31 | 2005-11-30 | 安姆根有限公司 | 刺激巨核细胞生长和分化的组合物及方法 |
| EP1377593B1 (en) * | 2001-03-26 | 2005-12-28 | Novartis AG | 2-amino-propanol derivatives |
| EP1511473B8 (en) * | 2002-05-27 | 2013-07-24 | Novartis AG | Bis-aromatic alkanols |
| US7612238B2 (en) * | 2002-09-13 | 2009-11-03 | Novartis Ag | Amino-propanol derivatives |
| JP2004307440A (ja) * | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩 |
| CA2523677A1 (en) * | 2003-04-30 | 2004-11-11 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
-
2004
- 2004-02-11 MX MXPA05008531A patent/MXPA05008531A/es active IP Right Grant
- 2004-02-11 WO PCT/US2004/004006 patent/WO2004071442A2/en not_active Ceased
- 2004-02-11 EP EP04710227A patent/EP1594508B1/en not_active Expired - Lifetime
- 2004-02-11 ES ES04710227T patent/ES2393551T3/es not_active Expired - Lifetime
- 2004-02-11 CA CA002515638A patent/CA2515638A1/en not_active Abandoned
- 2004-02-11 PL PL378134A patent/PL378134A1/pl not_active Application Discontinuation
- 2004-02-11 BR BRPI0407401-7A patent/BRPI0407401A/pt not_active IP Right Cessation
- 2004-02-11 JP JP2006503494A patent/JP4505449B2/ja not_active Expired - Fee Related
- 2004-02-11 AU AU2004210697A patent/AU2004210697B2/en not_active Ceased
- 2004-02-11 US US10/776,946 patent/US7256206B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517591A5 (https=) | ||
| JP6496823B2 (ja) | 新規置換インダゾール、その製造方法、前記新規置換インダゾールを含む医薬製剤、および薬剤を製造するための前記新規置換インダゾールの使用 | |
| ES2934181T3 (es) | Inhibidores de la interacción MDM2-P53, basados en isoindolinona, con actividad antineoplásica | |
| KR20170081204A (ko) | 제약 화합물 | |
| JP2009526761A5 (https=) | ||
| JP2019031560A5 (https=) | ||
| JP2007538024A5 (https=) | ||
| JP2009523724A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| JP2008513496A5 (https=) | ||
| JP2010539171A (ja) | 高血圧を処置するためのチアゾリジンジオン類似体 | |
| GEP20115213B (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
| US11401278B2 (en) | Macrocyclic indole derivatives | |
| JP2006524669A5 (https=) | ||
| JP2008513506A5 (https=) | ||
| JP2008513498A5 (https=) | ||
| JP2010539110A5 (https=) | ||
| CZ243093A3 (en) | Benzofuran derivatives, process of their preparation and pharmaceutical preparations in which they are comprised | |
| JP2009539943A5 (https=) | ||
| JP2021501178A (ja) | 虚血性脳卒中の治療のための芳香族スルホンアミド誘導体 | |
| JP2019520344A5 (https=) | ||
| JP2025512995A (ja) | カンナビノイド受容体１アンタゴニスト／インバースアゴニスト及びその使用 | |
| JP2007537287A5 (https=) | ||
| JP2010514733A5 (https=) | ||
| JP2019512534A5 (https=) |